Included Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Included Health provides comprehensive health navigation and care delivery for employers, specializing in complex conditions, mental health, and LGBTQ+ healthcare needs.
About
Included Health is a digital health company formed through the 2021 merger of Grand Rounds Health and Doctor On Demand, creating a unified platform for health navigation and virtual care delivery for employer health plans. The company provides members with access to expert second opinions, specialist referrals, primary care, mental health services, and benefits navigation through a single integrated platform. Included Health has built specialized expertise in serving populations with complex care needs including members with serious diagnoses, those seeking LGBTQ+-affirming care, and employees navigating mental health challenges. The company raised over $300M and serves large self-insured employers as a comprehensive health benefit that supplements traditional insurance. The merger combined Grand Rounds' navigation and expert medical opinion capabilities with Doctor On Demand's virtual primary care and psychiatry platform, creating broader clinical coverage than either company offered independently. Included Health positions itself as a health equity platform that improves outcomes for all employees regardless of their health complexity, geographic location, or demographic characteristics.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.